688 related articles for article (PubMed ID: 24036844)
21. Discovery of adamantane based highly potent HDAC inhibitors.
Gopalan B; Ponpandian T; Kachhadia V; Bharathimohan K; Vignesh R; Sivasudar V; Narayanan S; Mandar B; Praveen R; Saranya N; Rajagopal S; Rajagopal S
Bioorg Med Chem Lett; 2013 May; 23(9):2532-7. PubMed ID: 23538115
[TBL] [Abstract][Full Text] [Related]
22. Sensitization of tumor cells by targeting histone deacetylases.
Perego P; Zuco V; Gatti L; Zunino F
Biochem Pharmacol; 2012 Apr; 83(8):987-94. PubMed ID: 22120677
[TBL] [Abstract][Full Text] [Related]
23. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
24. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
26. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
29. Targeting the epigenome for the treatment and prevention of lung cancer.
Schrump DS; Nguyen DM
Semin Oncol; 2005 Oct; 32(5):488-502. PubMed ID: 16210090
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
31. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT; Bernards R
Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylation as a target for radiosensitization.
Cerna D; Camphausen K; Tofilon PJ
Curr Top Dev Biol; 2006; 73():173-204. PubMed ID: 16782459
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors in cancer therapy.
Rasheed WK; Johnstone RW; Prince HM
Expert Opin Investig Drugs; 2007 May; 16(5):659-78. PubMed ID: 17461739
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
Vendetti FP; Rudin CM
Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential for HDAC inhibitors in the heart.
McKinsey TA
Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
Mottamal M; Zheng S; Huang TL; Wang G
Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
[TBL] [Abstract][Full Text] [Related]
37. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
[TBL] [Abstract][Full Text] [Related]
38. Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy.
Ahmad M; Hamid A; Hussain A; Majeed R; Qurishi Y; Bhat JA; Najar RA; Qazi AK; Zargar MA; Singh SK; Saxena AK
DNA Cell Biol; 2012 Oct; 31 Suppl 1():S62-71. PubMed ID: 22462686
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylases and cancer: causes and therapies.
Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
